\ Welcome

The Citoxlab Group offers a comprehensive range of pre-clinical services for pharmaceutical, biotechnology, chemicals, cosmetics, medical devices and food companies worldwide. Our scientists and regulatory experts provide customized advice to help your development projects progress in the most effective way.

The Citoxlab Group has more than

1300 employees working in France, Canada, Denmark, Hungary and USA.

Proximity, the latest technologies and easy access to scientists, make Citoxlab your one-stop CRO for pre-clinical research. We offer maximum flexibility and expertise, major factors that guarantee the quality of your non-clinical programs.

Let’s build our future together !

\ News

  • 30/04/19

    MIXiii Biomed 2019

    May 14-16, 2019

    Tel Aviv, Israel

  • 29/04/19

    WILMINGTON, MA, April 29, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments.

    Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing.  With operations in Europe and North America, the acquisition of Citoxlab will further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which will enhance the Company’s ability to partner with clients across the drug discovery and development continuum.

    James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “Citoxlab’s complementary service offering and geographic footprint are an excellent strategic fit and will enable us to enhance the support we can provide for our clients’ early-stage research efforts.  The addition of Citoxlab’s talented staff, extensive scientific capabilities, and client-centric approach solidifies our leading position in the outsourced safety assessment market at a time when we believe there is and will continue to be significant client demand for these outsourced services.  We are pleased to welcome the exceptional team at Citoxlab to the Charles River family, and look forward to working together to help our clients discover and develop new drugs for the patients who need them.”

    Caution Concerning Forward-Looking Statements

    This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters.  Forward-looking statements include statements in this news release regarding the acquisition of Citoxlab and Charles River’s expectations with respect to the impact of Citoxlab on Charles River, its service offerings, client perception, revenue, revenue growth rates, and earnings; Charles River’s projected future performance including revenue and earnings per share; Charles River’s expected operational synergies; as well as Charles River’s future growth in the area of safety assessment.  Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements.  Those risks and uncertainties include, but are not limited to, the ability to successfully integrate the acquisition of Citoxlab.  A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River’s Annual Report on Form 10-K as filed on February 13, 2019, as well as other filings we make with the Securities and Exchange Commission.  Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

    About Charles River

    Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.  Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

    # # #


    Investor Contact:                                                      Media Contact:

    Todd Spencer                                                            Amy Cianciaruso

    Corporate Vice President, Investor Relations    Corporate Vice President, Public Relations

    781.222.6455                                                            781.222.6168
    todd.spencer@crl.com                                              amy.cianciaruso@crl.com

    View the original release 

  • 16/04/19

    Immuno-oncology now represents a real therapeutic breakthrough and is still rapidly evolving. Within just a few years, immunotherapies have been approved as an important treatment option for many cancer patients.
    Pharmaceutical and biotech companies face significant pressure to accelerate immuno-oncology drug candidates from discovery to clinical use. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Comprehensively addressing pharmacology issues, compound manufacturing and toxicology strategies, and designing appropriate clinical trials can result in accelerating immuno-oncology product development, and mitigating timelines, costs and regulatory risks.
    This free event will focus on a number of key considerations for transitioning an immuno-oncology product from discovery to clinical trials, including:
    • Efficiency assessment in tumor models,
    • Manufacturing
    • Toxicology and safety evaluation 
    • Clinical trial design
    The final program will be available soon.
    Sympo MUNICH
  • 24/01/19

    14th Annual Biomarkers Congress

    February 21-22, 2019

    Manchester, UK

  • 24/01/19

    Citoxlab Symposium in La Jolla

    May 9th, 2019

    La Jolla, CA

  • 24/01/19

    Citoxlab Symposium in San Francisco

    May 7th, 2019

    San Francisco, CA